MRS Measurement of Glutamate and GABA Metabolism in Brain

This study is currently recruiting participants. (see Contacts and Locations)
Verified August 2013 by National Institutes of Health Clinical Center (CC)
Sponsor:
Information provided by:
National Institutes of Health Clinical Center (CC)
ClinicalTrials.gov Identifier:
NCT00109174
First received: April 22, 2005
Last updated: July 2, 2014
Last verified: August 2013

April 22, 2005
July 2, 2014
April 2005
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00109174 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
MRS Measurement of Glutamate and GABA Metabolism in Brain
MRS (Magnetic Resonance Spectroscopy) Measurement of Glutamate and GABA Metabolism in Brain

This study will use magnetic resonance spectroscopy (MRS) to measure in the brain the transfer of [13]C as it is naturally metabolized from glucose to specific chemical transmitters. From this method, we can measure the rate of production of an important excitatory neurotransmitter (glutamate) as well as an inhibitory neurotransmitter (GABA).

(13)C is a stable (i.e., non-radioactive) isotope of carbon with a natural abundance of approximately 1%. Following infusion of [(13)C]glucose and/or [(13)C]acetate, in vivo MRS (magnetic resonance spectroscopy) can monitor the rate of flux of the (13)C atom from glucose and/or acetate to glutamate to glutamine. Thus, this procedure can provide measure of glutamate (GLU) and glutamine (GLN) turnover in brain. We have established parameters to obtain these measurements in nonhuman primate brain. The current protocol seeks approval to optimize MRS parameters for human brain using the GE 3T, and the Siemens 7T device.

Interventional
Not Provided
Primary Purpose: Treatment
Healthy
Procedure: Magnetic Resonance Spectroscopy
N/A
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
120
Not Provided
Not Provided
  • INCLUSION CRITERIA:

Age: 18-65 years

Diagnosis: Healthy

EXCLUSION CRITERIA:

Abnormal fasting blood glucose level (normal values are 70-115 mg/dL); All subjects must have a fasting blood glucose level of within the normal values of 70-115 mg/dL

Serious medical illness (including diabetes) as determined from H& P or laboratory testing; All subjects must meet none of the Axis I diagnoses

Prescription psychotropic medication; drug free period must be greater than 3 weeks for anticholinergics and benzodiazepine and greater than 8 weeks for fluoxetine, antipsychotics, anticonvulsants

Claustrophobia

Pregnancy; All women with child-bearing potential will have a blood and/or urine pregnancy test within 24 hours prior to the MRS study to exclude pregnancy

Any condition that increases risk for MRI (e.g., pacemaker, metallic foreign body in the eye, etc.)

Unable to lay on one's back for MRI/MRS scans

Positive HIV test

Both
18 Years to 65 Years
Yes
Contact: Maria D Ferraris Araneta, C.R.N.P. (301) 496-9423 ferrarism@mail.nih.gov
Contact: Shizhe Steve Li, Ph.D. (301) 435-8859 steveli@mail.nih.gov
United States
 
NCT00109174
050144, 05-M-0144
Not Provided
Not Provided
National Institute of Mental Health (NIMH)
Not Provided
Principal Investigator: Shizhe Steve Li, Ph.D. National Institute of Mental Health (NIMH)
National Institutes of Health Clinical Center (CC)
August 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP